Bio-Rad Laboratories (BIO.B) vs CONMED (CNMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed CONMED (CNMD) over the past year, gaining 28.2% versus a loss of 3.0%. Over five years, BIO.B leads with a -50.5% price change compared with -68.2% for CNMD. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $1.35 billion), about 7.2 times the size.
On valuation, CONMED trades at a lower trailing P/E (24.3x vs 46.3x for Bio-Rad Laboratories). CONMED pays a dividend yielding 0.44%, while Bio-Rad Laboratories does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | CNMD |
|---|---|---|
| Share price | $365.08 | $45.03 |
| Market cap | $9.76B | $1.35B |
| 1-day change | 0.00% | -0.18% |
| YTD return | +17.50% | +11.11% |
| 1-year return | +28.15% | -3.03% |
| 5-year return | -50.54% | -68.24% |
| P/E ratio (TTM) | 46.27 | 24.34 |
| Forward P/E | — | 9.42 |
| EPS (TTM) | $7.89 | $1.85 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.20 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | — |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $365.08 | $53.66 |
| 52-week low | $244.54 | $31.44 |
| Distance from 52-week high | 0.00% | -16.08% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1.04% |
| Average volume | 6 | 482.58K |
| Shares outstanding | 5.06M | 29.95M |
| Employees | 7,450 | 3,900 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 7.2 times larger than CONMED by market value ($9.76B vs $1.35B).
- BIO.B has outperformed CNMD by 31.2 percentage points over the past year.
- Bio-Rad Laboratories trades at a higher earnings multiple (46.3x vs 24.3x trailing P/E).
- The two companies sit in different sectors: Bio-Rad Laboratories in Healthcare and CONMED in Health Care.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,900 employees
BIO.B vs CNMD FAQ
Which is bigger, Bio-Rad Laboratories or CONMED?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $1.35B for CONMED (CNMD).
Which stock has performed better over the past year, BIO.B or CNMD?
BIO.B returned +28.15% over the past 12 months, compared with -3.03% for CNMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or CNMD?
CNMD has the lower trailing P/E at 24.3, versus 46.3 for BIO.B. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bio-Rad Laboratories or CONMED?
CONMED pays a dividend yielding 0.44%, while Bio-Rad Laboratories does not currently pay a regular dividend.
Are Bio-Rad Laboratories and CONMED in the same industry?
No. Bio-Rad Laboratories is in the Healthcare sector, while CONMED is in Health Care.